Condition
Pancreatic Mucinous-Cystic Neoplasm
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Completed2
Unknown1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02110498Completed
Early Detection of Pancreatic Cystic Neoplasms
NCT03188991Phase 2CompletedPrimary
Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
NCT02494388Terminated
Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions
NCT02213419Phase 1UnknownPrimary
Endoscopic Ultrasonography-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort Study
Showing all 4 trials